pirtobrutinib
E888599
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| pirtobrutinib canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T10837770 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: pirtobrutinib Context triple: [Bruton tyrosine kinase, isTherapeuticTargetOf, pirtobrutinib]
-
A.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: pirtobrutinib Target entity description: Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
A.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
non-covalent BTK inhibitor ⓘ small molecule drug ⓘ targeted therapy ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| binds | BTK in a reversible manner ⓘ |
| developedBy | Eli Lilly and Company ⓘ |
| hasAdministrationFrequency | once daily ⓘ |
| hasApprovalType | accelerated approval in the United States ⓘ |
| hasATCCode | L01EL04 ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
bruising ⓘ cough ⓘ diarrhea ⓘ fatigue ⓘ neutropenia ⓘ pneumonia ⓘ thrombocytopenia ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDrugClass |
antineoplastic agent
ⓘ
protein kinase inhibitor ⓘ |
| hasGeneration | next-generation BTK inhibitor ⓘ |
| hasIndicationStatus | for patients previously treated with at least two lines of systemic therapy including a BTK inhibitor in mantle cell lymphoma ⓘ |
| hasMechanismOfAction | BTK inhibition ⓘ |
| hasMolecularTargetClass | tyrosine kinase ⓘ |
| hasPharmacologicClass | BTK inhibitor ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for BTK ⓘ |
| hasTarget | Bruton tyrosine kinase ⓘ |
| hasTherapeuticArea |
hematologic oncology
ⓘ
lymphoid malignancies ⓘ |
| hasTradeName | Jaypirca ⓘ |
| isActiveAgainst | BTK C481S mutation ⓘ |
| isCovalent | no ⓘ |
| isDesignedToOvercome | resistance to covalent BTK inhibitors ⓘ |
| isNonCovalent | yes ⓘ |
| isSubstrateOf |
CYP3A
ⓘ
linked to:
CYP3A4
|
| isTakenBy | adult patients ⓘ |
| isUsedFor |
B-cell malignancies
ⓘ
other relapsed or refractory B-cell lymphomas ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ relapsed or refractory small lymphocytic lymphoma ⓘ |
| metabolism | hepatic ⓘ |
| reduces |
B-cell proliferation
ⓘ
survival of malignant B cells ⓘ |
| regulates | B-cell receptor signaling ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: pirtobrutinib Description of subject: Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.